GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Cyclically Adjusted Book per Share

Astellas Pharma (STU:YPH) Cyclically Adjusted Book per Share : €4.53 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Astellas Pharma's adjusted book value per share for the three months ended in Mar. 2024 was €5.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.53 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Astellas Pharma's average Cyclically Adjusted Book Growth Rate was 6.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 7.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Astellas Pharma was 7.30% per year. The lowest was 4.00% per year. And the median was 5.00% per year.

As of today (2024-06-06), Astellas Pharma's current stock price is €9.326. Astellas Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €4.53. Astellas Pharma's Cyclically Adjusted PB Ratio of today is 2.06.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.97. And the median was 2.90.


Astellas Pharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Astellas Pharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Cyclically Adjusted Book per Share Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.95 4.66 4.83 4.82 4.53

Astellas Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 4.52 4.62 4.71 4.53

Competitive Comparison of Astellas Pharma's Cyclically Adjusted Book per Share

For the Drug Manufacturers - General subindustry, Astellas Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Cyclically Adjusted PB Ratio falls into.



Astellas Pharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Astellas Pharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.466/107.2000*107.2000
=5.466

Current CPI (Mar. 2024) = 107.2000.

Astellas Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201406 4.020 98.000 4.397
201409 4.241 98.500 4.616
201412 4.234 97.900 4.636
201503 4.612 97.900 5.050
201506 4.457 98.400 4.856
201509 4.553 98.500 4.955
201512 4.631 98.100 5.061
201603 4.712 97.900 5.160
201606 4.889 98.100 5.343
201609 5.223 98.000 5.713
201612 5.219 98.400 5.686
201703 5.100 98.100 5.573
201706 5.348 98.500 5.820
201709 5.039 98.800 5.467
201712 5.070 99.400 5.468
201803 4.905 99.200 5.301
201806 5.059 99.200 5.467
201809 5.102 99.900 5.475
201812 5.267 99.700 5.663
201903 5.313 99.700 5.713
201906 5.423 99.800 5.825
201909 5.799 100.100 6.210
201912 5.820 100.500 6.208
202003 5.834 100.300 6.235
202006 5.807 99.900 6.231
202009 5.756 99.900 6.177
202012 5.835 99.300 6.299
202103 5.781 99.900 6.203
202106 5.625 99.500 6.060
202109 5.903 100.100 6.322
202112 6.152 100.100 6.588
202203 6.120 101.100 6.489
202206 5.949 101.800 6.265
202209 6.364 103.100 6.617
202212 6.014 104.100 6.193
202303 5.864 104.400 6.021
202306 5.736 105.200 5.845
202309 5.782 106.200 5.836
202312 5.340 106.800 5.360
202403 5.466 107.200 5.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Astellas Pharma  (STU:YPH) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Astellas Pharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=9.326/4.53
=2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Astellas Pharma was 3.62. The lowest was 1.97. And the median was 2.90.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Astellas Pharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (STU:YPH) Business Description

Industry
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.

Astellas Pharma (STU:YPH) Headlines

No Headlines